> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Anacor Submits NDA for Dermatitis Treatment
- URL: https://www.fdaweb.com/anacor-submits-nda-for-dermatitis-treatment/
- Published: 2016-01-07T12:00:00.000Z
- Updated: 2026-09-15T02:25:43.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5134379

Anacor Pharmaceuticals has submitted an NDA for crisaborole topical ointment, 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4), for treating mild-to-moderate atopic dermatitis in children and adults. According to the company, crisaborole is a novel boron-containing small molecule believed to inhibit PDE-4 in target cells, which reduces the production of pro-inflammatory cytokines thought to cause the signs and symptoms of atopic dermatitis. The company reported the results of two Phase 3 studies 7/2015 in which crisaborole achieved statistically significant results on all primary and secondary endpoints and demonstrated a safety profile consistent with previous studies. In October, Anacor also reported that its long-term safety study showed that crisaborole was well-tolerated and demonstrated a safety profile consistent with the profile in the Phase 3 studies when used intermittently for up to 12 months.